申请人:Hangzhou Innogate Pharma Co., Ltd.
公开号:EP3686196A1
公开(公告)日:2020-07-29
The present invention provides polycyclic compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC. Specifically, the present invention provides compounds represented by the following formula (I), wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an antitumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the antitumor response rate of the antibody and broaden the types of tumors to be treated.
本发明提供了作为 IDO 抑制剂和/或 IDO-HDAC 双重抑制剂的多环化合物。具体而言,本发明提供了由下式(I)代表的化合物,其中各基团的定义如说明书所述。这些化合物具有 IDO 抑制活性或 IDO-HDAC 双重抑制活性,可用于预防或治疗与 IDO 和/或 IDO-HDAC 活性或表达水平相关的疾病。同时,本发明的化合物可以与抗肿瘤抗体如 PD-1 和 PD-L1 结合使用,这样的结合可以大大提高抗体的抗肿瘤反应率,扩大治疗肿瘤的种类。